eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
6/2005
vol. 9
 
Share:
Share:
abstract:

Effectiveness and toxicity of complex chemoimmunotherapy for treatment of patients with metastatic melanoma

Jerzy Tujakowski
,
Krzysztof Roszkowski
,
Bogdan Żurawski

Współcz Onkol (2005); vol. 9: 6: 269-272
Online publish date: 2005/09/06
View full text Get citation
 
Background and purpose: Metastatic melanoma is considered to be highly resistant to treatment. Authors of this work attempted to treat patients suffering from melanoma metastases using chemoimmunotherapy and evaluate the benefit and the toxicity of such treatment. The clinical effects and toxicity of treatment were estimated.
Material and methods: 12 patients aged from 23 to 61 years took part in the research. The period of observation lasted from 4 to 11 months. The schedule of treatment included CCNU, Dacarbasine, Cisplastine, Interferon-alfa, Interleukine-2 and Tamoxifen. The cycle of treatment was repeated every 21 days. 3 to 6 courses were assumed to be administered.
Results: In 3 patients the PD answer was determined, in 5 patients the ND answer, in 3 the PD answer, 1 person did not report after the first course. In 8 patients the third and fourth degree of hematological toxicity according to WHO was identified while in 4 patients the second degree was identified. In the majority of patients the treatment was stopped because of increasing toxicity. The average time of survival was 5 months.
Conclusion: Taking into consideration the toxicity of the therapy and small percentage of positive answers, according to this schedule chemoimmunotherapy connected with hormonotherapy is not justified in clinical practice.
keywords:

melanoma metastases, chemoimmunotherapy, toxicity of therapy

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.